Two Onc Docs

This week’s episode will be focusing on Gastric Adenocarcinoma. We will go over all the important details on risk factors, diagnostic work-up, staging and treatment for both local regional disease and metastatic disease with updates in 2025 since we last covered this topic in 2023.

We are updating another important GYN ONC topic: endometrial (uterine) cancer. We will go over all the important details on the risk factors, presentation, diagnosis, staging & treatment options. We will also cover rare uterine malignancies at the end of the episode.

Join oncologists Dr. Tom Powles and Dr. Brian Rini as they dive into the latest strategies for managing metastatic renal cell carcinoma. They discuss the importance of risk stratification and patient characteristics in treatment selection. The conversation covers the evolving role of cytoreductive nephrectomy, the significance of immunotherapy breaks, and the complexities of side effects from tyrosine kinase inhibitors. Listen for insights on tailored approaches for various RCC subtypes and career advice for budding oncologists!

Join renowned oncologists Tom Powles, a leading expert in GU oncology from Barts Cancer Center, and Brian Rini, a pioneer in clinical trials at Vanderbilt, as they delve into the latest insights on localized renal cell carcinoma. They explore critical risk factors, including smoking and genetic conditions like von Hippel-Lindau syndrome. The duo examines evolving treatment strategies, including nephrectomy, ablative techniques, and the emerging role of immune therapies, shedding light on their potential impacts on patient outcomes.

This week’s episode will be focusing on Cervical Cancer with some updates since we last released this topic in 2022. We will go over important details on prevention, risk factors, diagnosis & treatment.

This week’s episode is an update on a must-know topics both for new fellows & residents. We will go over clinically important oncologic emergencies including brain metastases, hypercalcemia of malignancy, cord compression and SVC syndrome. 

This week’s episode will be focusing on one of the GI plenary session abstracts presented at the ASCO Annual Meeting 2025,  the MATTERHORN trial: phase 3 durvalumab + FLOT which is 5FU leucovorin, oxaliplatin and docetaxel in resectable gastric or GE junction CA. 

This week’s episode will be focusing on how to prepare for the start of heme/onc fellowship! We will go over some general advice on how to succeed, study tips and resources we used throughout fellowship as well as some tips on how to stay academically productive during training if you are planning for an academic career.

Delve into groundbreaking advancements in breast cancer treatment with discussions on the SERENA-6 trial. The focus is on the promising combination of camisetrant and CDK 4/6 inhibitors for advanced hormone receptor-positive cases. Highlights include impressive progression-free survival improvements and the innovative use of circulating tumor DNA in managing patient care. Concerns about safety profiles and how these findings integrate into current practices add depth to the conversation.

This discussion highlights the latest updates on ovarian cancer, focusing on often-overlooked symptoms that can lead to late diagnoses. It dives into the importance of genetic testing for BRCA1-2 mutations in treatment approaches. The hosts detail treatment protocols, advocating for surgical interventions when possible, and explore the emerging maintenance therapies that show promise in improving patient outcomes. They also clarify the unique characteristics of various ovarian cancer types, reinforcing the need for personalized treatment strategies.